CRP and coronary artery disorder: Genetic studies suggest that inhibiting either IL-6 or complement could prove beneficial in patients with CAD (24–26), and it has recently been shown that a single dose of tocilizumab attenuates the increase in CRP and PCI-related TnT release in NSTEMI patients (15).